Creatine supplementation synergizes with the anti-PD-1 therapy to yield superior antitumor efficacy [44], because creatine may activate tumor infiltrating CD8 T cells via an energy-buffering mechanism that is non-redundant to the mechanisms utilized by ICB therapies. Here, CD8A is linked to neoplasm.